Flow cytometry analysis revealed that CD4+CD8+ T cells increased from 1.39% (control group) to 5.22% (NZCB + US group), while for CD4−CD8+ T cells, the population markedly increased from 16.60% (control group) to 27.50% (NZCB + US group), indicating the activated anti-tumor T cell immunity (Fig. 6h; Additional file 1: Fig. S33). This evidence concerns the gene CD4 and neoplasm.